Acetyholine antibodies found in Sz post mortem

Chandley, M. J., M. N. Miller, et al. (2009). “Increased antibodies for the alpha7 subunit of the nicotinic receptor in schizophrenia.” Schizophr Res109(1-3): 98-101

Many association studies show that acetylcholinereceptors such as nicotinicreceptors or muscarinic receptors are related to schizophrenia.(Freedman, Leonard et al. 2001)

Alpha 7 CNS nicotinic acetylcholine receptor is a widely accepted gene linking to schizophrenia. In postmortem studies, the acetylcholine receptor numbers are severely decreased in schizophrenia patients.(Gault, Hopkins et al. 2003)

so, if you’re immune system heats up, like if you’re sick, you are emotionally upset, you are hot, you exercise too much, your immune system triggers your psychosis.

http://vixra.org/pdf/1204.0070v1.pdf

1 Like

Tired of reading This stuff

2 Likes

Realistically what percentage of psychosis/schizophrenia is caused by acetyholine problems?

that is something the researchers are still looking at. here are all the research papers cited by the individual who wrote the research paper to support his statement that Sz is autoimmune . it doesn’t paste well, so here again, is the link to the paper, and there’s quite a bit about it on the NIH or PubMed website as well

http://vixra.org/pdf/1204.0070v1.pdf
Schizophrenia is a TH2 dominant autoimmune disease possibly against acetylcholine receptorsof CNS

References
Abdeljaber, M. H., M. P. Nair, et al.
(1994). “Depressed natural killer cell activity in
schizophrenic patients.”
Immunol Invest
23
(4

5): 259

Abramovitz, B., I. Altboum, et al. (1991). “Induction of serotonin release from mast
cells by lymphocyte activators is dependent upon implantation of lymphocyte
plasma membrane components.”
Exp Cell Res
194
(2): 228

Achiron, A., S. Noy, et al. (1994).
"T

cell subsets in acute psychotic schizophrenic
patients."
Biol Psychiatry
35
(1): 27

Akhondzadeh, S., M. Tabatabaee, et al. (2007). "Celecoxib as adjunctive therapy in
schizophrenia: a double

blind, randomized and placebo

controlled trial."
Schizophr
Res
90
(1

3): 179

Akiyama, K. (1999). "Serum levels of soluble IL

2 receptor alpha, IL

6 and IL

1
receptor antagonist in schizophrenia before and during neuroleptic
administration."
Schizophr Res
37
(1): 97

Albrecht, P., E. F. Torrey, et al. (1980)
. "Raised cytomegalovirus

antibody level in
cerebrospinal fluid of schizophrenic patients."
Lancet
2
(8198): 769

Bock, E., B. Weeke, et al. (1970). “Immunoglobulins in schizophrenic patients.”
Lancet
2
(7671): 523.
Borda, T., R. Perez Rivera, et al.
(2002). “Antibodies against cerebral M1 cholinergic
muscarinic receptor from schizophrenic patients: molecular interaction.”
J
Immunol
168
(7): 3667

Chandley, M. J., M. N. Miller, et al.
(2009). “Increased antibodies for the alpha7
subunit of the nico
tinic receptor in schizophrenia.”
Schizophr Res
109
(1

3):
98

Chittiprol, S., G. Venkatasubramanian, et al. (2009). "Beta2

microglobulin
abnormalities in antipsychotic

naive schizophrenia: evidence for immune
pathogenesis."
Brain Behav Immun
23
(2): 189

Chowdari, K. V., K. Xu, et al.
(2001). “Immune related genetic polymorphisms and
schizophrenia among the Chinese.”
Hum Immunol
62
(7): 714

Cosentino, M., A. M. Fietta, et al. (2007). “Human CD4+CD25+ regulatory T cells
selectively express tyrosin
e hydroxylase and contain endogenous
catecholamines subserving an autocrine/paracrine inhibitory functional
loop.”
Blood
109
(2): 632

Dalack, G. W., D. J. Healy, et al. (1998). “Nicotine dependence in schizophrenia:
clinical phenomena and laboratory fi
ndings.”
Am J Psychiatry
155
(11):
1490

Drexhage, R. C., T. A. Hoogenboezem, et al. (2011). "An activated set point of T

cell
and monocyte inflammatory networks in recent

onset schizophrenia patients
involves both pro

and anti

inflammatory forces."
I
nt J
Neuropsychopharmacol
14
(6): 746

Fox, G. B., T. A. Esbenshade, et al.
(2005). "Pharmacological properties of ABT

239
[4

(2

{2

[(2R)

2

Methylpyrrolidinyl]ethyl}

benzofuran

5

yl)benzonitrile]: II.
Neurophysiological characterization and broad preclinical efficacy in cognition
and schizophrenia of a potent and selective histami
ne H3 receptor
antagonist."
J Pharmacol Exp Ther
313
(1): 176

Freedman, R., S. Leonard, et al. (2001). "Linkage disequilibrium for schizophrenia at
the chromosome 15q13

14 locus of the alpha7

nicotinic acetylcholine
receptor subunit gene (CHRNA7)."
Am
J Med Genet
105
(1): 20

Freudenreich, O., M. A. Brockman, et al. (2010). "Analysis of peripheral immune
activation in schizophrenia using quantitative reverse

transcription
polymerase chain reaction (RT

PCR)."
Psychiatry Res
176
(2

3): 99

Gaufo, G.
O. and M. C. Diamond (1996). "Prolactin increases CD4/CD8 cell ratio in
thymus

grafted congenitally athymic nude mice."
Proc Natl Acad Sci U S A
93
(9): 4165

Gault, J., J. Hopkins, et al. (2003). “Comparison of polymorphisms in the alpha7
nicotinic re
ceptor gene and its partial duplication in schizophrenic and control
subjects.”
Am J Med Genet B Neuropsychiatr Genet
123B
(1): 39

Goodman, A. B. (1995). “Chromosomal locations and modes of action of genes of the
retinoid (vitamin A) system support their involvement in the etiology of
schizophrenia.”
Am J Med Genet
60
(4): 335

Goodman, A. B. (1998). “Three independent lines of evi
dence suggest retinoids as
causal to schizophrenia.”
Proc Natl Acad Sci U S A
95
(13): 7240

Hallgren, R., P. Venge, et al. (1982). “Elevated serum levels of lactoferrin and
eosinophil cationic protein in schizophrenic patients.”
Br J Psychiatry
140
:
5
5

Handoko, H. Y., D. J. Nancarrow, et al. (2003). "Tumor necrosis factor haplotype
analysis amongst schizophrenia probands from four distinct populations in
the Asia

Pacific region."
Am J Med Genet B Neuropsychiatr Genet
121B
(1):
1

Henneberg, A. E.,
S. Horter, et al. (1994). “Increased prevalence of antibrain
antibodies in the sera from schizophrenic patients.”
Schizophr Res
14
(1):
15

Hikida, T., H. Jaaro

Peled, et al. (2007). "Dominant

negative DISC1 transgenic mice
display schizophrenia

associa
ted phenotypes detected by measures
translatable to humans."
Proc Natl Acad Sci U S A
104
(36): 14501

Ito, C. (2004). “The role of the central histaminergic system on schizophrenia.”
Drug
News Perspect
17
(6): 383

Jones, A. L., B. J. Mowry, et al. (2005). "Immune dysregulation and self

reactivity in
schizophrenia: do some cases of schizophrenia have an autoimmune basis?"
Immunol Cell Biol
83
(1): 9

Jun, T. Y., C. U. Pae, et al. (2003). "Interleukin

10 gene promot
er polymorphism is not
associated with schizophrenia in the Korean population."
Psychiatry Clin
Neurosci
57
(2): 153

Kinney, D. K., P. Teixeira, et al.
(2009). “Relation of schizophrenia prevalence to
latitude, climate, fish consumption, infant mortali
ty, and skin color: a role for
prenatal vitamin d deficiency and infections?”
Schizophr Bull
35
(3): 582

Laan, W., D. E. Grobbee, et al. (2010). "Adjuvant aspirin therapy reduces symptoms of
schizophrenia spectrum disorders: results from a randomized,
double

blind,
placebo

controlled trial."
J Clin Psychiatry
71
(5): 520

Leon

Ponte, M., G. P. Ahern, et al. (2007). "Serotonin provides an accessory signal to
enhance T

cell activation by signaling through the 5

HT7 receptor."
Blood
109
(8): 3139

L
eonard, B. E. (2005). “Is there an immunologic basis for schizophrenia?”
Expert Rev
Clin Immunol
1
(1): 103

Luria, E. A. and I. V. Domashneva (1974). “Antibodies to thymocytes in sera of
patients with schizophrenia.”
Proc Natl Acad Sci U S A
71
(1): 235

Maes, M., J. Delange, et al. (1997). “Acute phase proteins in schizophrenia, mania
and major depression: modulation by psychotropic drugs.”
Psychiatry Res
66
(1): 1

Mathew, S. V., A. J. Law, et al. (2007). “Alpha7 nicotinic acetylcholine receptor mRNA
expression and binding in postmortem human brain are associated with
genetic variation in neuregulin 1.”
Hum Mol Genet
16
(23): 2921

Mittleman, B. B., F. X. Castell
anos, et al. (1997). “Cerebrospinal fluid cytokines in
pediatric neuropsychiatric disease.”
J Immunol
159
(6): 2994

Mukherjee, S., S. P. Mahadik, et al. (1994). “Serum antibodies to nicotinic
acetylcholine receptors in schizophrenic patients.”
Schizop
hr Res
12
(2):
131

Muller, N., M. Riedel, et al. (2000). “The immune system and schizophrenia. An
integrative view.”
Ann N Y Acad Sci
917
: 456

Orange, P. R., P. R. Heath, et al. (1996). “Individuals with schizophrenia have an
increased incidence o
f the H2R649G allele for the histamine H2 receptor
gene.”
Mol Psychiatry
1
(6): 466

Pae, C. U., C. H. Yoon, et al. (2006). "Antipsychotic treatment may alter T

helper (TH)
2 arm cytokines."
Int Immunopharmacol
6
(4): 666

Pfeiffer, C. C., V. Iliev,
et al. (1971). “Blood histamine levels, basophil counts, and trace
metals in the schizophrenias.”
Psychopharmacol Bull
7
(3): 37.
Prell, G. D., J. P. Green, et al. (1995). “Histamine metabolites in cerebrospinal fluid of
patients with chronic schizophrenia:
their relationships to levels of other
aminergic transmitters and ratings of symptoms.”
Schizophr Res
14
(2):
93

Putheti, P., A. Awasthi, et al. (2010). "Human CD4 memory T cells can become
CD4+IL

9+ T cells."
PLoS One
5
(1): e8706.
Ramchand, R., J. We
i, et al.
(1994). “Increased serum IgE in schizophrenic patients
who responded poorly to neuroleptic treatment.”
Life Sci
54
(21): 1579

Rivero, O., J. Sanjuan, et al. (2010). “Serotonin transporter gene polymorphisms and
auditory hallucinations in psy
chosis.”
Rev Neurol
50
(6): 325

Roberts, G. W. (1991). “Schizophrenia: a neuropathological perspective.”
Br J
Psychiatry
158
: 8

Saetre, P., L. Emilsson, et al. (2007). "Inflammation

related genes up

regulated in
schizophrenia brains."
BMC
Psychiatry
7
: 46.
Saiz, P. A., M. P. Garcia

Portilla, et al.
(2006). "Interleukin

1 gene complex in
schizophrenia: an association study."
Am J Med Genet B Neuropsychiatr
Genet
141B
(6): 678

Schwimmbeck, P. L., T. Dyrberg, et al. (1989). "Molecular mimicry and myasthenia
gravis. An autoantigenic site of the acetylcholine receptor alpha

subunit that
has biologic activity and reacts immunochemically with herpes simplex virus."
J Clin Invest
84
(4
): 1174

Seok Jeong, B., J. S. Kwon, et al.
(2005). “Functional imaging evidence of the
relationship between recurrent psychotic episodes and neurodegenerative
course in schizophrenia.”
Psychiatry Res
139
(3): 219

Severance, E. G., J. Lin, et al.
(2011). "Dietary antigens, epitope recognition, and
immune complex formation in recent onset psychosis and long

term
schizophrenia."
Schizophr Res
126
(1

3): 43

Shi, J., D. F. Levinson, et al. (2009). “Common variants on chromosome 6p22.1 are
associated
with schizophrenia.”
Nature
460
(7256): 753

Sperner

Unterweger, B., A. Whitworth, et al. (1999). "T

cell subsets in schizophrenia:
a comparison between drug

naive first episode patients and chronic
schizophrenic patients."
Schizophr Res
38
(1): 61

Stefansson, H., R. A. Ophoff, et al. (2009). “Common variants conferring risk of
schizophrenia.”
Nature
460
(7256): 744

Stevens, J. D. (1962). "Dual function of psychotherapeutic antihistamine
(tranquilizer

antiallergic) in schizophrenia."
Dis Nerv Sys
t
23
: 416

Stevens, J. R. (1988). “Schizophrenia and multiple sclerosis.”
Schizophr Bull
14
(2):
231

Teixeira, A. L., H. J. Reis, et al.
(2008). “Increased serum levels of CCL11/eotaxin in
schizophrenia.”
Prog Neuropsychopharmacol Biol Psychiatry
3
2
(3): 710

Ueki, S., G. Mahemuti, et al.
(2008). “Retinoic acids are potent inhibitors of
spontaneous human eosinophil apoptosis.”
J Immunol
181
(11): 7689

Wang, C., J. McInnis, et al. (2001). "Long

term behavioral and neurodegenerative
effects of
perinatal phencyclidine administration: implications for
schizophrenia."
Neuroscience
107
(4): 535

Yang, Z. W., K. N. Chengappa, et al. (1994). "An association between
anti

hippocampal antibody concentration and lymphocyte production of IL

2
in patien
ts with schizophrenia."
Psychol Med
24
(2): 449

Yolken, R. H. and E. F. Torrey (1995). “Viruses, schizophrenia, and bipolar disorder.”
Clin Microbiol Rev
8
(1): 131

14

Acetyholine didn’t make hallucinations physically harm me twice.

You keep telling people that you aren’t sick but they can’t see.

My schizophrenia, it’s someone and not something.

From the paper:

Current theory saying that neurotransmitter imbalance such as serotonin or dopamine only provides limited effectiveness in schizophrenia treatment by drugs changing serotonin and dopamine concentration. Despite of such treatment, majority of schizophrenia patients still have very poor prognosis. Thus, the neurotransmitter imbalance theory is not correct.

Pretty big jump to say that because schizophrenia is difficult disease to treat that the established theories are wrong.

How effective is his treatment of schizophrenia? If it worked better than the established treatments then he might be on to something. If it doesn’t then he’s full of it.

1 Like

I don’t recall the writer’s exact title, but I believe he’s a Dr, from John Hopkins, moved back to his native country Taiwan. the writer is a doctor, not a patient.

the citations on the last 2 page of the paper, are other doctors and researchers, finding antibodies against acetycholine.

I’m learning there’s many antibodies against acetycholine, I’ve been tested for the 3 that have tests available on the market, and they are used predominately for MG, (eye drooping, muscle weakness caused by lack of acetycholine) Even if you have MG, this test comes back negative 10% of the time. Testing for acetycholine antibodies for MG is only available at this lab Arup, and at Mayo, I have been tested by both labs, all negative.

if you read the Sz research paper, they are looking at other antibodies against acetycholine that researches have found, but a test like this has not yet been developed, which is what a pdoc will tell you, there isn’t a test for Sz yet